Emergent BioSolutions (EBS) Tops Q3 EPS by 31c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $7.97 -2.57%
Revenue Growth %: +32.0%
Financial Fact:
Net income (loss) attributable to Emergent BioSolutions Inc.: 21.34M
Today's EPS Names:
CCEL, FEIM, PLG, More
Revenue Growth %: +32.0%
Financial Fact:
Net income (loss) attributable to Emergent BioSolutions Inc.: 21.34M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $1.21, $0.31 better than the analyst estimate of $0.90. Revenue for the quarter came in at $311.8 million versus the consensus estimate of $289.27 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
- UBS Reiterates Buy Rating on Dollar Tree (DLTR)
- UBS Reiterates Neutral Rating on Buckle, Inc. (BKE)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
